Vir Biotechnology (VIR) is back in focus after its two-drug regimen for chronic hepatitis delta hit all primary and key secondary targets in the pivotal Phase 3 ECLIPSE 1 study. The latest hepatitis ...
Source LinkVir Biotechnology (VIR) is back in focus after its two-drug regimen for chronic hepatitis delta hit all primary and key secondary targets in the pivotal Phase 3 ECLIPSE 1 study. The latest hepatitis ...
Source Link
Comments